Reaction

Thyroid Neoplasm reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,757 reports · 48 co-occurring drugs

As of the last recalculation, Thyroid Neoplasm appears in 2,757 FAERS reports alongside 48 co-occurring drug terms. The strongest observed disproportionality signal is TOFACITINIB CITRATE (PRR 16.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tofacitinib Citrate	28	16.3	16.3
Sulfasalazine	135	13.6	13.7
Alendronate Sodium	163	12.9	12.9
Liraglutide	79	12.4	12.4
Etonogestrel And Ethinyl Estradiol	34	11.7	11.7
Octreotide Acetate	46	11.5	11.5
Leflunomide	140	10.6	10.6
Celecoxib	168	10.2	10.2
Interferon Beta-1B	25	9.9	9.9
Valsartan And Hydrochlorothiazide	17	9.5	9.5
Ezetimibe And Simvastatin	18	9.0	9.0
Hydroxychloroquine	86	8.9	9.0
Risedronate Sodium	36	8.8	8.9
Lanreotide Acetate	9	8.7	8.7
Exenatide	58	8.5	8.5
Hydroxychloroquine Sulfate	99	8.5	8.5
Chlorhexidine Gluconate	10	8.3	8.3
Meperidine Hydrochloride	10	8.2	8.2
Abatacept	136	7.7	7.8
Levothyroxine Sodium	256	6.7	6.7
Interferon Beta-1A	141	5.8	5.8
Raloxifene Hydrochloride	11	5.7	5.7
Olmesartan Medoxomil	26	5.5	5.5
Sitagliptin And Metformin Hydrochloride	15	5.3	5.3
Fulvestrant	22	5.1	5.1
Extended Phenytoin Sodium	11	5.0	5.0
Rituximab	132	4.9	4.9
Amlodipine Besylate And Valsartan	7	4.8	4.8
Pioglitazone	27	4.8	4.8
Estrogens, Conjugated	36	4.6	4.6
Conjugated Estrogens	35	4.6	4.6
Imatinib Mesylate	16	4.4	4.4
Golimumab	43	3.8	3.8
Metformin Hcl	27	3.7	3.7
Etanercept	268	3.6	3.6
Nilotinib	14	3.6	3.6
Armodafinil	10	3.6	3.6
Teriparatide	51	3.5	3.5
Conjugated Estrogens And Medroxyprogesterone Acetate	9	2.9	2.9
Dofetilide	4	2.9	2.9
Oral Semaglutide	27	2.8	2.8
Naltrexone Hydrochloride And Bupropion Hydrochloride	3	2.7	2.7
Sodium Oxybate	22	2.5	2.5
Dulaglutide	29	2.5	2.5
Glatiramer Acetate	15	1.9	1.9
Somatropin	17	1.8	1.8
Tirzepatide	19	0.9	0.9
Levonorgestrel	22	0.8	0.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.